Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns - 2Find the Future of Outsourcing: Exploring the Gig Economy
- 310 Energizing Vocations in the Innovation Business
- 41st results from Blue Ghost lunar lander reveal how much we still don't know about the moon
- 5Honda’s Biggest Flex Isn’t Its Superbikes, It’s Selling 500K Bikes In One Month
- 25 of the world’s best sandwiches
- The Universe of Impeccable Pearls: A Manual for Valuable Gems
- The most effective method to Pick the Right Material Organization: Fundamental Tips
- Baidu robotaxi outage in Wuhan caused by 'system failure', police say
- It's time for Artemis II to break Apollo 13's distance record. What to know about the moon flyby
- Toyota Motor Europe to roll out smart EV charging through new partnerships
- Amateur's Manual for Venture Strategies for Tenderfoots
- Ocean side Locations for a Family Excursion
- Russian military plane crashes in annexed Crimea, killing 29 people on board
